PET-CT en pacientes con cáncer de esófago, colon y recto

Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, et al. PET/CT of Esophageal Cancer: Its Role in Clinical Management. Radiographics. 2007;27(6):1635-52. Review.

https://doi.org/10.1148/rg.276065742

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.

https://doi.org/10.3322/canjclin.55.2.74

Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al (editores). [Internet] SEER Cancer Statistics Review, 1975-2005 Bethesda: National Cancer Institute. [citado: 3 agosto 2010] Disponible en http://seer.cancer.gov/csr/1975_2005/.

National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Program. Public-Use Data Fast Stats (1975-2004 y 2001-2005). [Internet]. Bethesda: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. [Citado: 8 julio 2010], Disponible en: http://seer.cancer.gov/statfacts/html/>melan.html.

Ángel L, Giraldo A, Pardo C. Mortalidad por cánceres del aparato digestivo en Colombia entre 1980 y 1998. Análisis de tendencias y comparación regional. Rev Fac Medicina (Universidad Nacional de Colombia), 2004;52(1):19-37.

Piñeros M, Murillo R. Incidencia de cáncer en Colombia: importancia de las fuentes de información en la obtención de cifras estimativas. Rev Colomb Cancerol. 2004;8(1):5-14.

Colombia, Departamento Administrativo Nacional de Estadística. Estadísticas Vitales-Defunciones no fetales. [Internet] Bogotá: DANE; 2008 [citado 10 junio 2010]. Disponible en: http://www.dane.gov.co/daneweb_V09/index.php2008.

Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEERMedicare data. Med Care. 2002;40(8 Suppl):IV-104-17.

https://doi.org/10.1097/00005650-200208001-00014

España, Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Agencia de Evaluación de Tecnologías Sanitarias. PET-TAC: Indicaciones, revisión sistemática y meta-análisis. Madrid: Agencia de Evaluación de Tecnologías Sanitarias; 2004.

Poland, Agency for Health Technology Assessment in Poland. Cost-effectiveness analysis of PET-CT positron emission tomography and the diagnostic technologies financed from public sources in oncological diagnostic in Poland. Clinical and epidemiological aspects. Warszawa-Nowy Sacz, Agency for Health Technology Assessment in Poland; 2006.

Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007;11(44):iii-iv, xi-267.

https://doi.org/10.3310/hta11440

Sachelarie I, Kerr K, Ghesani M, Blum RH. Integrated PETCT: evidence-based review of oncology indications. Oncology. 2005;19(4):481-90.

Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007;48 Suppl 1:78S-88S.

Podoloff DA, Advani RH, Allred C, Benson AB 3rd, Brown E, Burstein HJ, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007;5Suppl 1:S1-S22.

Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2005;129(6):1232-41.

https://doi.org/10.1016/j.jtcvs.2004.12.042

Kula Z, Pietrzak T, Kobus-Blachinio K, Zuchora Z. Combined positron emission tomography and computed tomography (PET/CT) imaging in staging esophageal cancer - analysis of 12 cases. Wspólcz Onkol. 2005;9(8):336-41.

Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003 Nov;44(11):1797-803.

Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006;16(1):80-7.

https://doi.org/10.1007/s00330-005-2767-0

Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol. 2004;30(3):286-91.

https://doi.org/10.1016/j.ejso.2003.10.023

Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK, et al. Potential impact of [18F]3'- deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-Dglucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging. 2003;30(7):988-94.

https://doi.org/10.1007/s00259-003-1187-0

Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240(6):1027-34.

https://doi.org/10.1097/01.sla.0000146145.69835.c5

Even-Sapir E, Parag Y, Lerman H, Gutman M, Levine C, Rabau M, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology. 2004;232(3):815-22.

https://doi.org/10.1148/radiol.2323031065

Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005;46(4):587-95.